In a major move to boost ease of doing business and advance clinical research in India, the Union Health Ministry has announced proposed amendments to the New Drugs and Clinical Trials Rules, 2019. The amendments aim to simplify the process of obtaining test licenses and submitting applications for bioavailability (BA) and bioequivalence (BE) studies, key components in drug development and approval.

Under the new rules, the current system of acquiring test licenses will be replaced by a notification and intimation system. Applicants will no longer have to wait for test licenses except for a limited category of high-risk drugs but need only inform the Central Licensing Authority. This will reduce the statutory processing time sharply from 90 days to 45 days, halving the delays currently faced by stakeholders.

The changes also dispense with some licensing requirements for certain BA and BE studies, further reducing regulatory hurdles. Collectively, these reforms are expected to cut the number of license applications by approximately 50%, accelerating the initiation of clinical trials and drug testing.

These amendments signal a commitment by the government to regulatory reform in the pharmaceutical and clinical research sectors, enhancing India’s position as a global hub for pharma innovation and research. The Ministry has invited public comments on the draft amendments published in the Gazette of India, continuing an open consultation process.

The reforms promise to optimize resource deployment by the Central Drugs Standard Control Organisation (CDSCO) and promote faster drug development timelines, benefiting pharma companies, researchers, and ultimately patients relying on timely access to innovative therapies.

This initiative is aligned with the Government of India’s vision to strengthen the pharmaceutical industry through streamlined regulations, better compliance, and enhanced global integration.

Medgate Today will continue monitoring the developments and provide updates on these important changes shaping India’s pharmaceutical regulatory landscape.